Pfizer Inc (PFE MU) stock market data APIs
€21.1752
0.09(0.4%)
as of October 14, 2025
Try our APIs with
free plan!
Pfizer Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for PFE.MU.
Prev. Close
21.1752
Open
21.2679
High
21.3741
Low
21.1752
52 wk Range
18.1725-25.6307
Market Cap
262 316 M
Dividends (Yield)
0.0341
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Top Novavax Shareholder Demands Company’s Sale
Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself. Continue Reading View Comments
Health Care Roundup: Market Talk
Find insight on Johnson & Johnson, Japanese pharmaceutical stocks and more in the latest Market Talks covering the health care sector. Continue Reading View Comments
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark drug-prici...
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CorMedix CRMD has experienced significant growth in 2025, fueled by the strong uptake of the company’s lead marketed drug, DefenCath (Taurolidine + Heparin). The FDA approved CorMedix’s DefenCath ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
